C/CPublished research associates this genotype (two copies of the reported risk allele) with a higher likelihood of Ticagrelor levels in individuals with acute coronary syndromes treated with ticagrelor compared to the general population. (GWAS Catalog, Eur Heart J 2015, PMID:25935875)
C/TPublished research associates this genotype (one copy of the reported risk allele) with an intermediate association with Ticagrelor levels in individuals with acute coronary syndromes treated with ticagrelor. (GWAS Catalog, Eur Heart J 2015, PMID:25935875)
T/TPublished research associates this genotype with typical/baseline likelihood of Ticagrelor levels in individuals with acute coronary syndromes treated with ticagrelor — no copies of the reported risk allele. (GWAS Catalog, Eur Heart J 2015, PMID:25935875)
rs188845491 is a single position in the genome, in or near the CYP3A5 gene. Published research associates it with ticagrelor levels in individuals with acute coronary syndromes treated with ticagrelor. A single variant does not decide an outcome — it shifts a probability, and for most common variants the shift is small.
Does rs188845491 affect how medicines work?
CYP3A5 carries pharmacogenomic findings for Tacrolimus. That is educational information, not a prescription or a dosing guide. Any decision to start, stop or change a medicine belongs with the clinician or pharmacist managing your treatment.
Does having rs188845491 mean I will get this?
No. Common variants like this one move a probability slightly and, on their own, rarely decide anything about one person. Nothing on this page is a diagnosis, and health decisions should be made with a clinician who can see your whole picture.
Where does the information about rs188845491 come from?
GWAS Catalog, Eur Heart J 2015, PMID:25935875. Every variant on MyGeneLog comes from public primary sources and is published with its citation and the date it was checked.